Showing 351-360 of 3714 results for "".
- Soligenix Initiates Phase 2 Trial of SGX302 for Mild to Moderate Psoriasishttps://practicaldermatology.com/news/soligenix-initiates-phase-2-trial-of-sgx302-for-mild-to-moderate-psoriasis/2461471/Patient enrollment has been opened for Soligenix, Inc.'s Phase 2a study evaluating SGX302 (synthetic hypericin) for the treatment of mild to moderate psoriasis. "We are excited to expand synthetic hypericin's development into different cutaneous T-cell diseases such as psoriasis, as a component of…
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month-1/2461411/November is Hyperhidrosis Awareness Month and the International Hyperhidrosis Society (IHhS) is committed to raising awareness of this medical condition that affects 365 million people worldwide, of which 27 percent go undiagnosed. In the United States alone, more than 15 million Americans have h…
- Daxxify from Revance Gets FDA Greenlighthttps://practicaldermatology.com/news/daxxify-from-revance-gets-fda-greenlight/2461331/Daxxify™ (DaxibotulinumtoxinA-lanm) from Revance is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults. Daxxify is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum albumin and a…
- Boehringer Ingelheim's Spevigo Is first Treatment FDA-Approved for GPPhttps://practicaldermatology.com/news/boehringer-ingelheims-spevigo-is-first-treatment-fda-approved-for-gpp/2461327/FDA has approved Spevigo (spesolimab) from Boehringer Ingelheim as the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spevigo is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a key part of a signaling path…
- ASLMS Announces New Officershttps://practicaldermatology.com/news/aslms-announces-new-officers-1/2461215/Paul M. Friedman, MD is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Friedman, board-certified by the American Board of Dermatology, is the director of Dermatology & Laser Surgery Center of Houston, Texas. He is a clinical assistant professor at the Univers…
- Skyrizi Gets Psoriatic Arthritis Indicationhttps://practicaldermatology.com/news/skyrizi-gets-psoriatic-arthritis-indication/2461049/Skyrizi® (risankizumab-rzaa) from AbbVie is now approved for the treatment of adults with active psoriatic arthritis (PsA). FDA approval is supported by data from two pivotal studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated the efficacy and safety of Skyrizi in adults with active PsA, including …
- ASLMS Announces New Officershttps://practicaldermatology.com/news/aslms-announces-new-officers/2460816/Henry H.L. Chan, MD, PhD, FRCP, is the new President of the American Society for Laser Medicine and Surgery (ASLMS). Dr. Chan is currently the Honorary Clinical Professor and Honorary Consultant Dermatologist of the Division of Dermatology, Department of Medicine, The University of Hong Kong, Quee…
- AAD Survey: One-Third of Americans Flunk Basic Quiz on Skin Cancer and Sun Exposurehttps://practicaldermatology.com/news/aad-survey-one-third-of-americans-flunk-basic-quiz-on-skin-cancer-and-sun-exposure/2460785/One-third of Americans lack a basic understanding of skin cancer and sun protection, according to a recent survey of 1,000 U.S. adults from the American Academy of Dermatology. Shockingly, more than half (53%) of adults are unaware that shade can protect them from the sun’s harmful ultraviolet ray…
- Expert Opinion: Fleshing Out the Role of Biosimilars in Dermatologyhttps://practicaldermatology.com/news/expert-opinion-fleshing-out-the-role-of-biosimilars-in-dermatology/2460742/Two new studies of biosimilars of tumor necrosis factor blockers that are used to treat a number of dermatologic conditions suggest that they are equivalent to their originator drugs, but there may be more involved in making the decision about switching to a biosimilar than lower cost. Reporting t…
- FDA Defers Approval of Revance's Toxin Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://practicaldermatology.com/news/fda-defers-approval-of-revances-toxin-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2460628/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication received on November 24…